Robert C. Hermann

2.5k total citations
38 papers, 1.8k citations indexed

About

Robert C. Hermann is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Robert C. Hermann has authored 38 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Robert C. Hermann's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Treatment and Pharmacology (11 papers) and Colorectal Cancer Treatments and Studies (7 papers). Robert C. Hermann is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Treatment and Pharmacology (11 papers) and Colorectal Cancer Treatments and Studies (7 papers). Robert C. Hermann collaborates with scholars based in United States and France. Robert C. Hermann's co-authors include John D. Hainsworth, F. Anthony Greco, Martin R. Weber, Shaker R. Dakhil, Thomas J. Lynch, Sharlene Litchy, James E. Bradof, John H. Barton, Gerry Ann Houston and Peter L. Silbert and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.

In The Last Decade

Robert C. Hermann

38 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert C. Hermann United States	15	1.0k	868	449	397	284	38	1.8k
B.Y. Yeap United States	20	805 0.8×	1.0k 1.2×	595 1.3×	563 1.4×	295 1.0×	65	2.0k
Héctor Soto Parrà Italy	24	1.3k 1.3×	1.6k 1.9×	257 0.6×	258 0.6×	168 0.6×	101	2.3k
B. Audhuy France	20	986 1.0×	316 0.4×	492 1.1×	437 1.1×	375 1.3×	48	1.9k
Jerome H. Goldschmidt United States	16	1.3k 1.3×	1.0k 1.2×	221 0.5×	356 0.9×	97 0.3×	68	1.9k
Tara Baetz Canada	20	904 0.9×	391 0.5×	514 1.1×	317 0.8×	261 0.9×	71	1.5k
Lucia Nogová Germany	24	683 0.7×	642 0.7×	698 1.6×	314 0.8×	184 0.6×	86	1.5k
Anas Gazzah France	22	1.3k 1.3×	861 1.0×	186 0.4×	553 1.4×	135 0.5×	99	2.1k
Giuseppe Badalamenti Italy	25	1.0k 1.0×	764 0.9×	212 0.5×	621 1.6×	108 0.4×	144	2.3k
Young Wha Koh South Korea	26	892 0.9×	563 0.6×	343 0.8×	407 1.0×	69 0.2×	82	1.7k
Markus Raderer Austria	20	598 0.6×	380 0.4×	296 0.7×	197 0.5×	212 0.7×	62	1.5k

Countries citing papers authored by Robert C. Hermann

Since Specialization

Citations

This map shows the geographic impact of Robert C. Hermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert C. Hermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert C. Hermann more than expected).

Fields of papers citing papers by Robert C. Hermann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert C. Hermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert C. Hermann. The network helps show where Robert C. Hermann may publish in the future.

Co-authorship network of co-authors of Robert C. Hermann

This figure shows the co-authorship network connecting the top 25 collaborators of Robert C. Hermann. A scholar is included among the top collaborators of Robert C. Hermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert C. Hermann. Robert C. Hermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hermann, Robert C., et al.. (2016). Development of a multidisciplinary program for evaluation and treatment of pancreatic cancer in a community healthcare system.. Journal of Clinical Oncology. 34(4_suppl). 303–303. 1 indexed citations

Spigel, David R., Jyoti D. Patel, Craig H. Reynolds, et al.. (2015). Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(2). 353–359. 22 indexed citations

Reynolds, Craig H., Jyoti D. Patel, Edward B. Garon, et al.. (2014). Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 16(3). 200–208. 7 indexed citations

Patel, Jyoti D., Edward B. Garon, Ramaswamy Govindan, et al.. (2013). Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC).. Journal of Clinical Oncology. 31(15_suppl). 8012–8012. 4 indexed citations

Pillai, Rathi N., Camille Ragin, Gabriel Sica, et al.. (2013). Human papillomavirus (HPV)-associated early stage non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 31(15_suppl). 7560–7560. 4 indexed citations

Garon, Edward B., Jyoti D. Patel, Scott P. Myrand, et al.. (2013). Translational research (TR) results from pointbreak: A randomized, open-label, phase III study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance pem+bev (Pem Arm) versus paclitaxel (Pac)+cb+bev followed by maintenance bev (Pac Arm) in patients (pts) with stage IIIB or IV nonsquamous non-small cell lung cancer (ns-NSCLC).. Journal of Clinical Oncology. 31(15_suppl). 8086–8086. 2 indexed citations

Patel, Jyoti D., Mark A. Socinski, Edward B. Garon, et al.. (2013). PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 31(34). 4349–4357. 281 indexed citations

Berlin, Jordan, Johanna C. Bendell, Lowell L. Hart, et al.. (2012). A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer. Clinical Cancer Research. 19(1). 258–267. 143 indexed citations

Spigel, David R., Jyoti D. Patel, Craig H. Reynolds, et al.. (2012). Patient-reported outcomes from POINTBREAK: The randomized, open-label, phase III study of pemetrexed (pem) + carboplatin (cb) + bevacizumab (bev) followed by maintenance pem + bev versus paclitaxel (pac) + cb + bev followed by maintenance bev in patients with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC).. Journal of Clinical Oncology. 30(34_suppl). 53–53. 2 indexed citations

10.

Hudis, C., Robert C. Hermann, Grace Makari‐Judson, et al.. (2011). 5026 POSTER DISCUSSION Sorafenib (SOR) Plus Chemotherapy (CRx) for Treatment (tx) of Patients (pts) With HER2-negative Locally Advanced (adv) or Metastatic (met) Breast Cancer (BC) and Prior Bevacizumab (BEV): Subgroup Analysis of AC01B07. European Journal of Cancer. 47. S338–S338. 1 indexed citations

11.

Bendell, Johanna C., John Nemunaitis, S. Vukelja, et al.. (2011). Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 29(33). 4394–4400. 81 indexed citations

12.

Khambata‐Ford, Shirin, Christopher Harbison, Donald Woytowitz, et al.. (2009). K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial. Journal of Clinical Oncology. 27(15_suppl). 8021–8021. 17 indexed citations

13.

Greco, F. Anthony, David R. Spigel, John H. Barton, et al.. (2006). Weekly bortezomib in the treatment of patients (pts) with previously treated multiple myeloma: A phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 24(18_suppl). 7547–7547. 6 indexed citations

14.

Gray, J. R., John D. Hainsworth, Anthony A. Meluch, et al.. (2005). Concurrent paclitaxel/carboplatin/infusional 5-FU/radiation therapy (RT) with or without subsequent esophageal resection in patients with localized esophageal cancer: A Minnie Pearl Cancer Research Network trial. Journal of Clinical Oncology. 23(16_suppl). 4018–4018. 7 indexed citations

15.

Widemann, Brigitte C., Frank M. Balis, Aiman Shalabi, et al.. (2004). Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2. JNCI Journal of the National Cancer Institute. 96(20). 1557–1559. 39 indexed citations

16.

Greco, F. Anthony, Sharlene Litchy, Robert C. Hermann, et al.. (2004). Carcinoma of unknown primary site with unfavorable characteristics: Survival of 396 patients after treatment with five consecutive phase II trials by the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 22(14_suppl). 4186–4186. 2 indexed citations

17.

Greco, F. Anthony, Joan B. Erland, Lisa H. Morrissey, et al.. (2000). Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Annals of Oncology. 11(2). 211–215. 80 indexed citations

18.

Cofield, Robert H., et al.. (1996). Neurologic complications after total shoulder arthroplasty. Journal of Shoulder and Elbow Surgery. 5(1). 53–61. 148 indexed citations

19.

Gastineau, Dennis A., Thomas M. Habermann, & Robert C. Hermann. (1989). Severe neuropathy associated with low-dose recombinant interferon-alpha. The American Journal of Medicine. 87. 116–116. 3 indexed citations

20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact